NEW YORK – Cellino Biotech on Monday announced that it has raised $16 million in a seed financing round, which it will put toward advancing its artificial intelligence-based platform for autologous cell- and tissue-based therapies.
Cambridge, Massachusetts-based Cellino's seed financing was co-led by The Engine and Khosla Ventures, with participation from Humboldt Fund and 8VC. "This seed financing round enables us to build towards a democratized future for autologous cells and tissues," Cellino CEO and Cofounder Nabiha Saklayen said in a statement.
Cellino's technology is rooted in laser editing, robotics, and machine learning, and is designed with the goal of automating pluripotent stem cell production. Autologous cell therapy, to date, has faced limitations when it comes to manufacturing, and Cellino views its platform as a solution to these limits. The platform, according to Cellino, is able to engineer "high-functionality cells with unrivaled consistency and yield."